Work

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

Year: 2016

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw401

Authors: J.F. Liu, K.N. Moore, M.J. Birrer, S. Berlin, U.A. Matulonis, J.R. Infante, B. Wolpin, K.A. Poon, R. Firestein, J. Xu, R. Kahn, Y. Wang, K. Wood, W.C. Darbonne, M.R. Lackner, S.K. Kelley, X. Lu, Y.J. Choi, D. Maslyar, E.W. Humke, H.A. Burris

Institutions: Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Massachusetts General Hospital, New England Cancer Specialists, Tennessee Oncology, Genentech

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: AstraZeneca, Atara Biotherapeutics, Genentech

OpenAlex ID: W2544930253

FWCI: 9.356

Cites: 15

Cited by: 132

Related to: 10